Comparing Rosuvastatin and Atorvastatin for Coronary Artery Disease: LODESTAR Trial Analysis

A secondary analysis of the LODESTAR trial compared the long-term efficacy and safety of rosuvastatin and atorvastatin in adults with coronary artery disease. The study found that both statins showed comparable efficacy for the composite outcome of all-cause death, myocardial infarction, stroke, or any coronary revascularization at three years. Rosuvastatin was associated with lower LDL cholesterol levels but a higher risk of new-onset diabetes mellitus requiring antidiabetic medication and cataract surgery compared to atorvastatin.